Logotipo del repositorio
Logotipo del repositorio
 

Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2eng
dc.contributor.authorNavarro, Carla
dc.contributor.authorOrtega, Ángel
dc.contributor.authorSanteliz, Raquel
dc.contributor.authorGarrido, Bermary
dc.contributor.authorChacín, Maricarmen
dc.contributor.authorGalban, Néstor
dc.contributor.authorVera, Ivana
dc.contributor.authorBautista de Sanctis, Juan
dc.contributor.authorBermúdez, Valmore
dc.date.accessioned2022-11-17T20:13:19Z
dc.date.available2022-11-17T20:13:19Z
dc.date.issued2022
dc.description.abstractThe constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer.eng
dc.format.mimetypepdfspa
dc.identifier.citationNavarro, C., Ortega, Á., Santeliz, R., Garrido, B., Chacín, M., Galban, N., Vera, I., De Sanctis, J. B., & Bermúdez, V. (2022). Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches. Pharmaceutics, 14(6), 1303. https://doi.org/10.3390/pharmaceutics14061303eng
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics14061303
dc.identifier.issn19994923
dc.identifier.urihttps://hdl.handle.net/20.500.12442/11380
dc.language.isoengspa
dc.publisherMDPIspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourcePharmaceuticseng
dc.sourceVol. 14 Issue 6 (2022)eng
dc.subjectMetabolic reprogrammingeng
dc.subjecttumor microenvironmenteng
dc.subjectenergy metabolismeng
dc.subjectneoplasmseng
dc.subjectcarbohydrateseng
dc.subjectinflammationeng
dc.subjectImmunotherapyeng
dc.titleMetabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approacheseng
dc.type.driverinfo:eu-repo/semantics/articleeng
dc.type.spaArtículo científicospa
oaire.versioninfo:eu-repo/semantics/publishedVersioneng

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
2022_MDPI_Metabolic Reprogramming.pdf
Tamaño:
2.56 MB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca